510(k) device
ReWalk® 7 Personal Exoskeleton (50-20-0005)
Rewalk Robotics Ltd. Dba Lifeward · Powered Exoskeleton (PHL, Class II) · First FDA decision Mar 12, 2025, newest Mar 12, 2025Mobility impairmentSpinal cord injury and paralysis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
46
Naming "7 Personal"
MAUDE reports
1
Brand "7 Personal", since 2015
PubMed studies
121
Mentioning "7 Personal"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ReWalk® 7 Personal Exoskeleton (50-20-0005)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K241822 · Decided Mar 12, 2025 · 261 days after receipt
Device type: Powered Exoskeleton (PHL) · Physical Medicine & Rehabilitation
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "7 Personal", any status and sponsor, newest update first.
Casa Colina Hospital and Centers for HealthcareAcademic, hospital or other
NCT07858656 · 52 participants (planned) · Start Oct 16, 2026 · Primary completion Oct 16, 2027
Device: transauricular Vagal Nerve Stimulation; Sham Comparator · For: Stroke; Ischemic Cerebrovascular Accident; Ischemic Stroke and 1 more
Sites: Pomona, California
- Evaluating a Digital Aid to Improve ICD DecisionsPivotal-lookingRecruiting
Stanford UniversityAcademic, hospital or other
NCT07913204 · 600 participants (planned) · Start Oct 19, 2026 · Primary completion Dec 31, 2027
Device: Arm A: Online, patient-facing decision-making aid (app) with personalized risk information.; Arm B - Online, patient-facing decision-making app without personalized risk information. · For: Shared Decision-making
Sites: San Francisco, California; Greenville, North Carolina
- Continuous Glucose Monitoring and Dietary Self-Management in Adults in NamwonPivotal-lookingNot yet recruiting
Ji-Yeob ChoiAcademic, hospital or other
NCT07890740 · 860 participants (planned) · Start Nov 2, 2026 · Primary completion Sep 2027
Device: Continuous Glucose Monitoring With Application-Based Biofeedback · For: Prediabetes; Dietary Self-Management; Diabetes Mellitus, Type 2
Sites: Namwon, South Korea · 4 sites in all
43 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "7 Personal", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code PHL
57 reports: 7 malfunction, 50 injury, 0 death
Newest reports for this brand
3007615665-2026-00003 · Received Sep 28, 2026 · Event dated Sep 3, 2026
Device type: Powered Exoskeleton (PHL)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Limb Fracture
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "7 Personal"[tiab]. The summary above synthesizes these.
- A qualitative exploratory analysis of channeled content.
Anastasia J, Wahbeh H, Delorme A, et al. · Explore (NY) · 2020Research Support, Non-U.S. Gov't
- Diagnostic statements: a linguistic analysis of how clinicians communicate diagnosis.
Dahm MR, Crock C · Diagnosis (Berl) · 2022Research Support, Non-U.S. Gov't
- Sociodemographic Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory Dysfunction.
Mendes Paranhos AC, Nazareth Dias ÁR, Machado da Silva LC, et al. · JAMA Netw Open · 2022Research Support, Non-U.S. Gov't
- What influences physician opioid prescribing for children with acute pain?
Slim G, van Manen M, Fowler M, et al. · Br J Pain · 2023
- Technostress as source of physician burnout: An exploration of the associations between technology usage and physician burnout.
Bahr TJ, Ginsburg S, Wright JG, et al. · Int J Med Inform · 2023Research Support, Non-U.S. Gov't
- Identifying factors associated with UK veterinary nurse resignations through examination of veterinary practice data.
Schofield I, Jacklin BD · Vet Rec · 2023
- Applications of Platelet Concentrates (PCs) in Regenerative Onco-Urology: A Systematic Review of Literature.
Gottardo A, Tulone G, Pavan N, et al. · Int J Mol Sci · 2024Systematic Review
- Early Perinatal Workforce Adaptations to the COVID-19 Pandemic.
Vanderlaan J, Woeber K · J Perinat Neonatal Nurs · 2022
- Barriers to Completing Low Dose Computed Tomography Scan for Lung Cancer Screening.
Wong LY, Choudhary S, Kapula N, et al. · Clin Lung Cancer · 2024
- Burnout and Metabolic Syndrome in Female Nurses: An Observational Study.
Chico-Barba G, Jiménez-Limas K, Sánchez-Jiménez B, et al. · Int J Environ Res Public Health · 2019Observational Study, Research Support, Non-U.S. Gov't
- Use and benefit of information, communication, and assistive technology among community-dwelling older adults - a cross-sectional study.
Fotteler ML, Kocar TD, Dallmeier D, et al. · BMC Public Health · 2023Research Support, Non-U.S. Gov't
- [Cancellation in CMA: incidence and causes].
Guillén JM, Bernadó AJ, Solanas JA, et al. · Cir Esp · 2012English Abstract
Other devices of this type
Also filed under product code PHL.
- Indego(R)Parker-Hannifin Corporation · 510(k) 2018
- Atalante XWandercraft SAS · 510(k) 2025
- ReWalk P6.0Re Walk Robotics , Ltd. · 510(k) 2023
- EksoNREkso Bionics, Inc. · 510(k) 2022
- HAL for Medical Use(Lower Limb type)Cyberdyne, Inc. · 510(k) 2020
- Ekso (version 1.1) and Ekso GT (version 1.2)Ekso Bionics, Inc. · 510(k) 2016
- Trexo TheoTrexo Robotics, Inc. · 510(k) 2026
- EveWandercraft SAS · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.